A KidneyCAN Town Hall Event
Renowned clinical kidney cancer researchers Dr. Sumanta Pal and Dr. Laurence Albiges presented a retrospective of 2024 research breakthroughs, along with a look forward at what we can expect in 2025.
➦ Video and resources below!
If you are interested in hearing about more events like this, make sure you’re subscribed to our newsletter.
Implementation of Belzutifan
Expanded Indication for Kidney Cancer Drug: AACR
New Standard in Previously Treated RCC
Immunotherapy
Phase 3 TiNivo 2 Study Results
Adjuvant Therapy Can Improve Survival
Modulating the Microbiome
Chromophobe Renal Cell Cancer
Finding Specialized Care
Kidney Cancer SPOREs (Specialized Center of Excellence)
NCI’s Cancer Information Service
Finding Community & Support
KidneyCAN thanks all who participated in this special Town Hall event, including our experts Laurence Albiges and Sumanta Pal. Thank you as well to our patient and caregiver community for providing insights and resources in the chat and community social that followed the Town Hall.
Dr. Sumanta (Monty) Kumar Pal is a distinguished medical oncologist specializing in genitourinary cancers, including kidney, bladder, and prostate cancers. Serving as Co-Director of City of Hope’s Kidney Cancer Program and Chair of the Kidney and Bladder Cancer Disease Team, Dr. Pal is dedicated to advancing cancer research and treatment.
Remarkably, Dr. Pal began his medical education at UCLA at age 17 and completed his oncology fellowship at City of Hope, where he has been a faculty member since 2009. With over 500 publications in leading medical journals, he holds patents for innovative prostate cancer drugs and oversees a comprehensive portfolio of clinical trials for kidney and bladder cancer research on the West Coast. Dr. Pal’s collaborative approach aims to develop novel therapies for currently incurable diseases.
Dr. Laurence Albiges is a leading medical oncologist and Head of the Department of Medical Oncology at Gustave Roussy, one of Europe’s premier cancer centers. Her expertise centers on developing innovative treatments for metastatic kidney cancer and rare renal cell carcinoma subtypes. She actively leads translational research programs to advance these areas.
An accomplished author, Dr. Albiges has contributed to numerous publications in esteemed scientific journals and serves as an associate editor for European Urology Oncology. Her research excellence has been recognized with several awards, including the Conquer Cancer Foundation Merit Award at the ASCO Genitourinary Symposium in 2015. She holds influential positions on various scientific boards and committees, such as the European Association of Urology guidelines panel for kidney cancer and the European Society for Medical Oncology congress scientific committee.
We at KidneyCAN know how challenging it can be to keep up with research developments and how they could impact your treatment options. We hope the ideas presented in our Town Hall help you as you work with your doctor to manage your care for kidney cancer.
If you’re looking to connect with more people who share your challenges and can offer support, check out our Smart Patients forum.
Join Us!
Error: No connected account.
Please go to the Instagram Feed settings page to connect an account.
